Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-d3)-,1-oxide
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
Regorafenib N-Oxide-d3 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Regorafenib N-Oxide-d3 usage and description
Regorafenib N-oxide D3 is a deuterated derivative of Regorafenib, which is an orally administered multi-kinase inhibitor used for the treatment of various types of cancer. The deuterated form is used in clinical trials to determine the metabolic fate of the parent molecule. The chemical structure of Regorafenib N-oxide D3 consists of a phenylurea moiety, a pyridine ring, and a fluorinated phenyl group.
Regorafenib N-oxide D3 is a potent inhibitor of multiple kinases including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR). It also inhibits several other kinases such as c-KIT, RET, and BRAF. By inhibiting these kinases, Regorafenib N-oxide D3 disrupts the signaling pathways that are involved in cancer cell proliferation, angiogenesis, and metastasis.
The recommended dose of Regorafenib N-oxide D3 is dependent on the specific clinical trial in which it is used. The drug is typically administered orally, and the dosage may vary based on the patient's age, weight, and medical history. Patients receiving Regorafenib N-oxide D3 should be monitored for potential side effects, which may include fatigue, hand-foot skin reaction, diarrhea, and hypertension.
In conclusion, Regorafenib N-oxide D3 is a deuterated derivative of Regorafenib that is used in clinical trials to determine the metabolic fate of the parent molecule. It is a potent inhibitor of multiple kinases involved in cancer cell proliferation, angiogenesis, and metastasis. Regorafenib N-oxide D3 is typically administered orally, and the dosage may vary based on the specific clinical trial. Patients receiving this drug should be monitored for potential side effects.
